IRBT vs NVCR vs ISRG vs NKTR

For growth investors, Intuitive Surgical, Inc.

(ISRG) is the stronger pick with 20. 5% revenue growth year-over-year, versus -43. 9% for Nektar Therapeutics (NKTR). Intuitive Surgical, Inc. (ISRG) offers the better valuation at 57. 6x trailing P/E (43. 8x forward), making it the more compelling value choice. Analysts rate NovoCure Limited (NVCR) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Intuitive Surgical, Inc.

(ISRG) delivered a total return of +58. 7%, compared to -99. 9% for iRobot Corporation (IRBT). Over 10 years, the gap is even starker: ISRG returned +554. 2% versus IRBT's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Intuitive Surgical, Inc.

(ISRG) is the lower-risk stock at 1. 02β versus iRobot Corporation's 5. 21β — meaning IRBT is approximately 412% more volatile than ISRG relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 4% for iRobot Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Intuitive Surgical, Inc.

(ISRG) is pulling ahead at 20. 5% versus -43. 9% for Nektar Therapeutics (NKTR). On earnings-per-share growth, the picture is similar: iRobot Corporation grew EPS 55. 3% year-over-year, compared to -12. 1% for Nektar Therapeutics. Over a 3-year CAGR, ISRG leads at 17. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Intuitive Surgical, Inc.

(ISRG) is the more profitable company, earning 28. 4% net margin versus -297. 1% for Nektar Therapeutics — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus -236. 8% for NKTR. At the gross margin level — before operating expenses — NKTR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for NVCR: 99.

0% to $33. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Intuitive Surgical, Inc.

(ISRG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 02), +554. 2% 10Y return). iRobot Corporation (IRBT) carries a higher beta of 5. 21 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ISRG: +554. 2%, IRBT: -99. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (IRBT (Consumer Cyclical) and NVCR (Healthcare) and ISRG (Healthcare) and NKTR (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: IRBT is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock; ISRG is a mid-cap high-growth stock; NKTR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.